Project Grant HT94252410356
Award Date
9/15/24
Completion Date
9/14/27
Dollars Obligated
$548K
Federal Agency
Defense Health Agency
Awardee
Universität Basel (GCXQV9JENLH1)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Switzerland
Similar Awards
The U.S. Defense Health Agency awarded a $989,167 Project Grant to the University of Bern in Switzerland under the Military Medical Research and Development program (CFDA 12.420). The grant, effective from February 15, 2024 to February 14, 2027, supports research to define the role of the SWI/SNF chromatin remodeling complex in advanced metastatic castration-resistant prostate cancer (mCRPC) therapy resistance. Through this grant, the University of Bern will conduct basic, translational, and...
This federal Project Grant award of $219,568.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Universitat Bern to investigate the role of intestinal secreted microRNAs in regulating the gut microflora and their impact on inflammatory bowel disease. The research aims to improve understanding of the underlying mechanisms of this condition, which is of relevance to military health. The award has a performance...
The Department of the Army Medical Command awarded a $438,916 project grant to Universitat Bern in Switzerland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2026 to target PARP inhibitor resistance. Through this funding, Universitat Bern researchers will investigate medical solutions for targeting resistance to poly (ADP-ribose) polymerase inhibitors, an area of focus under the Military Medical...
This Project Grant from the Department of the Army Medical Command will provide $797,100 to the Centre Hospitalier Universitaire Vaudois (CHUV) in Switzerland from August 1, 2022 through July 31, 2026 to support understanding T-cell senescence to optimize ovarian cancer immunotherapy. The grant falls under the Military Medical Research and Development program (CFDA 12.420), which aims to transform healthcare for service members and the public through innovative biomedical research...
This federal Project Grant award, valued at $161,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "BREAST CANCER BRAIN METASTASES: INTEGRATING IMMUNOGENOMIC AND PHENOTYPIC VULNERABILITIES TO IMPROVE OUTCOMES", will support advanced biomedical research focused on transforming healthcare for military service members and the broader public. The award, with a performance period from April 1, 2025 to...
This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $187,821.00 to Universitat Bern in Switzerland to conduct research on "site-specific intra-articular 'on demand' immunosuppression for long term functional graft survival in joint allotransplantation in a large-animal model." The goal of this research is to develop new immunosuppressive therapies to improve outcomes for joint transplantation procedures. The...
This $485,597.91 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research at the Universite De Sherbrooke in Canada. The award will fund a 3-year project from August 1, 2024 to July 31, 2027 focused on understanding the "CONTRIBUTION OF ALTERNATIVE SPLICING TO NEUROFIBROMAGENESIS." The research aims to advance scientific knowledge in the area of neurological disorders, which...
This $490,602 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports the development of a clinical-grade spinal cord neuroprosthesis to alleviate locomotor deficits in people with Parkinson's disease. The award, effective September 1, 2025 through August 31, 2028, was granted to the Ecole Polytechnique Federale De Lausanne (EPFL), a prominent Swiss research university. Through this project, EPFL will...
The Universite De Geneve will receive $439,332 from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct research targeting PARP inhibitor resistance from September 1, 2022 to August 31, 2026. Through this four-year Project Grant, the Universite De Geneve will investigate medical solutions for the battlefield by exploring ways to overcome resistance to poly (ADP-ribose) polymerase inhibitors, which are a class of targeted...
This federal Project Grant award in the amount of $1,605,638.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant was awarded to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, a private research university and academic medical center. The grant funding supports research aimed at developing new methods for immune targeting of dormant tumor...